Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt Sells 24,802 Shares

Repligen Co. (NASDAQ:RGENGet Rating) CEO Anthony Hunt sold 24,802 shares of the firm’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $200.00, for a total value of $4,960,400.00. Following the sale, the chief executive officer now directly owns 194,667 shares in the company, valued at $38,933,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Repligen Trading Down 0.9 %

RGEN opened at $201.74 on Friday. The firm has a market cap of $10.98 billion, a P/E ratio of 79.74 and a beta of 0.95. Repligen Co. has a 12 month low of $137.21 and a 12 month high of $327.32. The stock has a 50-day moving average of $162.03 and a 200 day moving average of $172.56.

Repligen (NASDAQ:RGENGet Rating) last released its quarterly earnings results on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.72 by $0.20. The company had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The firm’s revenue was up 44.5% on a year-over-year basis. During the same quarter last year, the business posted $0.68 earnings per share. On average, research analysts forecast that Repligen Co. will post 3.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Greenwood Capital Associates LLC boosted its position in shares of Repligen by 1.7% during the fourth quarter. Greenwood Capital Associates LLC now owns 3,490 shares of the biotechnology company’s stock valued at $924,000 after buying an additional 60 shares during the period. Intrust Bank NA boosted its position in shares of Repligen by 3.6% during the fourth quarter. Intrust Bank NA now owns 1,908 shares of the biotechnology company’s stock valued at $505,000 after buying an additional 66 shares during the period. Exchange Traded Concepts LLC boosted its position in shares of Repligen by 2.3% during the second quarter. Exchange Traded Concepts LLC now owns 2,996 shares of the biotechnology company’s stock valued at $487,000 after buying an additional 68 shares during the period. Hancock Whitney Corp boosted its position in shares of Repligen by 0.7% during the fourth quarter. Hancock Whitney Corp now owns 10,682 shares of the biotechnology company’s stock valued at $2,829,000 after buying an additional 71 shares during the period. Finally, Veritable L.P. boosted its position in shares of Repligen by 4.8% during the first quarter. Veritable L.P. now owns 1,556 shares of the biotechnology company’s stock valued at $293,000 after buying an additional 71 shares during the period. Hedge funds and other institutional investors own 86.82% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. UBS Group assumed coverage on Repligen in a report on Wednesday. They set a “buy” rating and a $213.00 price target on the stock. StockNews.com assumed coverage on Repligen in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Craig Hallum reduced their target price on Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $288.86.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.